Trials / Completed
CompletedNCT02497157
Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
Phase II Trial of FOLFOXIRI + Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Academic / Other
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of fluorouracil (5-FU), levofolinate calcium (l-LV), oxaliplatin (L-OHP) and irinotecan hydrochloride hydrate (CPT-11) (FOLFOXIRI) plus bevacizumab in untreated metastatic colorectal cancer patients who harbor Uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) \*1/\*1, \*1/\*6 or \*1/\*28.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxaliplatin (L-OHP) | |
| DRUG | Irinotecan hydrochloride hydrate (CPT-11) | |
| DRUG | Continuous intravenous infusion of fluorouracil (CIV 5-FU) | |
| DRUG | Levofolinate calcium (l-LV) | |
| DRUG | Bevacizumab (Bmab) |
Timeline
- Start date
- 2015-05-21
- Primary completion
- 2019-06-01
- Completion
- 2019-06-01
- First posted
- 2015-07-14
- Last updated
- 2020-06-17
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02497157. Inclusion in this directory is not an endorsement.